SynCore Biotechnology Co (ROCO:4192) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SynCore Biotechnology Co EBITDA Margin % Related Terms
SynCore Biotechnology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4192 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, SynCore Biotechnology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SynCore Biotechnology Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SynCore Biotechnology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SynCore Biotechnology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SynCore Biotechnology Co (ROCO:4192) has a EBITDA Margin % of -108.18% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SynCore Biotechnology Co and its competitors. According to the industry distribution chart, SynCore Biotechnology Co ranks #505 out of 944 companies in the Biotechnology industry, placing it in the top 53.5%.
Is SynCore Biotechnology Co's EBITDA Margin % too high?
SynCore Biotechnology Co's current EBITDA Margin % is -108.18%. Based on the distribution chart, SynCore Biotechnology Co ranks #505 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SynCore Biotechnology Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SynCore Biotechnology Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SynCore Biotechnology Co ranks #505 out of 944 companies for EBITDA Margin %. This places SynCore Biotechnology Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SynCore Biotechnology Co and its competitors. SynCore Biotechnology Co's current EBITDA Margin % is -108.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynCore Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, SynCore Biotechnology Co (ROCO:4192) is currently considered Possible Value Trap. The stock's GF Value™ is NT$47.67, compared to a current price of NT$20.00 — trading 58% below its estimated fair value. The current EBITDA Margin % is -108.18%. SynCore Biotechnology Co's overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SynCore Biotechnology Co (ROCO:4192), the current EBITDA Margin % is -108.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SynCore Biotechnology Co (ROCO:4192) Overvalued in 2026?
Based on GuruFocus' analysis, SynCore Biotechnology Co stock appears to be undervalued.
The current stock price of NT$20.00 is trading 58% below its estimated GF Value™ of NT$47.67.
GuruFocus considers SynCore Biotechnology Co to be Possible Value Trap.
Key valuation signals for ROCO:4192:
EBITDA Margin %: -108.18%
GF Value™: NT$47.67 vs. price of NT$20.00 (58% below fair value)
No single metric tells the full story. See the ROCO:4192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SynCore Biotechnology Co Ltd is a biotechnology company. The pipeline products of the company include SB01 and 02, SB03, SB04, SB05, and Others. It is engaged in new drug development and sales, healthy food development and sales, medicine inspection, biotechnology services, and intellectual property. It operates in a single industry, the new drug development. The company generates the majority of its revenue from medical products and healthy food.
67GF Score
Get the complete analysis for ROCO:4192
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4192 has been successfully added to your 
